株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

薬物治療モニタリングの世界市場の予測 〜2020年:製品・技術 (イムノアッセイ・プロテオミクス技術)・薬剤クラス・エンドユーザー別

Therapeutic Drug Monitoring Market by Product (Consumables, Equipment), Technology (Immunoassays, Proteomic Technologies), Class of Drug (Antiepileptics, Antibiotics, Immunosuppressants), End User (Hospital Labs, Private Labs) - Global Forecast to 2020

発行 MarketsandMarkets 商品コード 355217
出版日 ページ情報 英文 143 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
薬物治療モニタリングの世界市場の予測 〜2020年:製品・技術 (イムノアッセイ・プロテオミクス技術)・薬剤クラス・エンドユーザー別 Therapeutic Drug Monitoring Market by Product (Consumables, Equipment), Technology (Immunoassays, Proteomic Technologies), Class of Drug (Antiepileptics, Antibiotics, Immunosuppressants), End User (Hospital Labs, Private Labs) - Global Forecast to 2020
出版日: 2016年03月23日 ページ情報: 英文 143 Pages
概要

薬物治療モニタリングの市場は2015年から2020年にかけて7.4%のCAGR (複合年間成長率) で推移し、2015年の17億8000万米ドルから、2020年には25億5000万米ドルの規模に成長すると予測されています。

当レポートでは、世界の薬物治療モニタリングの市場について調査し、市場および製品の概要、市場成長への各種影響因子および市場機会の分析、製品タイプ・技術・薬剤クラス・エンドユーザー・地域別の市場分析および市場成長予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 薬物治療モニタリング:市場概要
  • 地域・薬剤クラス別分析
  • 地域動向
  • 技術別市場
  • 薬物治療モニタリング機器市場:タイプ別

第5章 市場概要

  • イントロダクション
  • 市場区分
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 市場分析:製品別

  • イントロダクション
  • 薬物治療モニタリング用消耗品
  • 薬物治療モニタリング機器
    • イムノアッセイアナライザー
    • プロテオミクス技術
    • その他の機器

第7章 市場分析:技術別

  • イントロダクション
  • イムノアッセイ
    • CLIA法
    • CEDIA法
    • FPIA法
    • PETINIA法
  • プロテオミクス技術
    • LC-MS法
    • GC-MS法
  • その他の技術

第8章 市場分析:薬剤クラス別

  • イントロダクション
  • 抗てんかん薬
  • 抗不整脈薬
  • 免疫抑制剤
  • 抗生剤
  • 気管支拡張薬
  • 向精神薬
  • その他

第9章 市場分析:エンドユーザー別

  • イントロダクション
  • 病院ラボ
  • 商業・民間ラボ
  • その他

第10章 市場分析:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
  • アジア太平洋
  • その他の地域

第11章 競合環境

  • 概要
  • 競合状況・動向
    • 新製品の投入・製品の承認・特許
    • 買収
    • マーケティング&プロモーション
    • 合意
    • その他

第12章 企業プロファイル

  • ROCHE DIAGNOSTICS
  • SIEMENS HEALTHCARE
  • THERMO FISHER SCIENTIFIC, INC.
  • DANAHER CORPORATION
  • BIO-RAD LABORATORIES, INC.
  • ABBOTT LABORATORIES
  • AGILENT TECHNOLOGIES
  • BIOMERIEUX
  • ALERE INC.
  • 積水メディカル
    • 概要
    • 財務動向
    • 製品・サービス
    • 戦略
    • 発展動向、など

第13章 付録

図表

目次
Product Code: MD 4185

Focus on cost effectiveness of therapeutic drug monitoring and increase in R&D investments will boost the growth of therapeutic drug monitoring market

The therapeutic drug monitoring market is projected to reach USD 2.55 billion by 2020 from USD 1.78 billion in 2015, growing at a CAGR of 7.4% during the forecast period (2015-2020).

In this report, the therapeutic drug monitoring market is broadly segmented by product, technology, class of drug, end user, and region.

North America is expected to account for more than half the therapeutic drug monitoring market share in 2015. It is the prime market for therapeutic drug monitoring due to the high awareness and acceptance of the benefits of therapeutic drug monitoring and growing healthcare expenditure. Europe on the other hand is growing at a slower rate as the healthcare sector is recovering from the economic downturn and healthcare facilities are trying to minimize healthcare delivery costs. Growth in the APAC therapeutic drug monitoring market is comparatively slower due to the dearth of skilled healthcare personnel who can perform therapeutic drug monitoring tests with minimal errors.

From an insight perspective, this research report focuses on the qualitative data, future market size, share, and market potential of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and challenges) and technological trends in therapeutic drug monitoring. It mainly focuses on the emerging and high-growth segments of the therapeutic drug monitoring market and government initiatives across regions.

The competitive landscape covers the various strategies adopted by industry players to maintain their position in the therapeutic drug monitoring market. The company profiles comprise the basic views on the key players in the therapeutic drug monitoring market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares.

Reasons to Buy the Report:

This research report has focused on various levels of analysis-industry analysis (industry trends), market share analysis of top players and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth market segments; high-growth regions; and market drivers, restraints, and opportunities.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on galley equipment offered by the top players in the global therapeutic drug monitoring market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the therapeutic drug monitoring market
  • Market Development: Comprehensive information about lucrative emerging markets - the report analyzes the markets for therapeutic drug monitoring across regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global therapeutic drug monitoring market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global therapeutic drug monitoring market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
    • 2.2.2. KEY DATA FROM PRIMARY SOURCES
      • 2.2.2.1. Key industry insights
    • 2.2.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. THERAPEUTIC DRUG MONITORING: MARKET OVERVIEW
  • 4.2. GEOGRAPHICAL ANALYSIS: THERAPEUTIC DRUG MONITORING MARKET, BY CLASSES OF DRUG (2015)
  • 4.3. GEOGRAPHICAL SNAPSHOT OF THE THERAPEUTIC DRUG MONITORING MARKET, 2015
  • 4.4. THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY
  • 4.5. THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
  • 5.4. DRIVERS
    • 5.4.1. ADVANCES IN DRUG PHARMACOKINETICS AND PHARMACOGENETICS TO INCREASE THE DEMAND FOR THERAPEUTIC DRUG MONITORING
    • 5.4.2. USE OF TDM IN TRADITIONAL ANTICANCER THERAPIES
  • 5.5. RESTRAINTS
    • 5.5.1. LACK OF FINANCIAL PROVISION FOR CLINICAL INTERPRETATION OF TDM RESULTS
  • 5.6. OPPORTUNITIES
    • 5.6.1. ENABLING PERSONALIZED MEDICINE VIA THERAPEUTIC DRUG MONITORING WHILE REDUCING HEALTHCARE COSTS
  • 5.7. CHALLENGES
    • 5.7.1. DEARTH OF SKILLED PROFESSIONALS TO PERFORM TESTS AND INTERPRET RESULTS

6. THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. THERAPEUTIC DRUG MONITORING CONSUMABLES
  • 6.3. THERAPEUTIC DRUG MONITORING EQUIPMENT
    • 6.3.1. IMMUNOASSAY ANALYZERS
    • 6.3.2. PROTEOMICS TECHNOLOGIES
    • 6.3.3. OTHER EQUIPMENT

7. THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. IMMUNOASSAYS
    • 7.2.1. CHEMILUMINESCENT IMMUNOASSAY (CLIA)
    • 7.2.2. CLONED ENZYME DONOR IMMUNOASSAY (CEDIA)
    • 7.2.3. FLUORESCENCE POLARIZATION IMMUNOASSAY (FPIA)
    • 7.2.4. PARTICLE-ENHANCED TURBIDIMETRIC-INHIBITION IMMUNOASSAY (PETINIA)
  • 7.3. PROTEOMIC TECHNOLOGIES
    • 7.3.1. LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY (LC-MS)
    • 7.3.2. GAS CHROMATOGRAPHY/MASS SPECTROMETRY (GC-MS)
  • 7.4. OTHER TECHNOLOGIES

8. THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG

  • 8.1. INTRODUCTION
  • 8.2. ANTIEPILEPTICS
  • 8.3. ANTIARRHYTHMIC DRUGS
  • 8.4. IMMUNOSUPPRESSANTS
  • 8.5. ANTIBIOTICS
  • 8.6. BRONCHODILATORS
  • 8.7. PSYCHOACTIVE DRUGS
  • 8.8. OTHER DRUG CLASSES

9. THERAPEUTIC DRUG MONITORING MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. HOSPITAL LABS
  • 9.3. COMMERCIAL/PRIVATE LABS
  • 9.4. OTHER END USERS

10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
  • 10.4. ASIA-PACIFIC
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. COMPETITIVE SITUATION AND TRENDS
    • 11.2.1. NEW PRODUCT LAUNCHES, PRODUCT APPROVALS, AND PATENTS
    • 11.2.2. ACQUISITIONS
    • 11.2.3. MARKETING AND PROMOTIONS
    • 11.2.4. AGREEMENTS
    • 11.2.5. OTHERS

12. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 12.1. INTRODUCTION
  • 12.2. ROCHE DIAGNOSTICS
  • 12.3. SIEMENS HEALTHCARE
  • 12.4. THERMO FISHER SCIENTIFIC, INC.
  • 12.5. DANAHER CORPORATION
  • 12.6. BIO-RAD LABORATORIES, INC.
  • 12.7. ABBOTT LABORATORIES
  • 12.8. AGILENT TECHNOLOGIES
  • 12.9. BIOMERIEUX
  • 12.10. ALERE INC.
  • 12.11. SEKISUI MEDICAL CO. LTD.

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 2: GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 3: NORTH AMERICA: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 4: GLOBAL THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 5: NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 6: GLOBAL THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 7: GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 8: GLOBAL PROTEOMIC TECHNOLOGIES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 9: GLOBAL OTHER EQUIPMENT MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 10: GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 11: IMMUNOASSAYS IN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 12: IMMUNOASSAY IN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 13: CLIA IN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 14: CEDIA IN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 15: FPIA IN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 16: PETINIA IN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 17: PROTEOMIC TECHNOLOGIES IN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 18: PROTEOMIC TECHNOLOGIES IN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 19: LC-MS IN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 20: GC-MS IN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 21: OTHER THERAPEUTIC DRUG MONITORING TECHNOLOGIES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 22: GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLASS OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 23: GLOBAL ANTIEPILEPTICS MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 24: NORTH AMERICA: ANTIEPILEPTICS MONITORING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 25: GLOBAL ANTIARRHYTHMIC DRUGS MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 26: NORTH AMERICA: ANTIARRHYTHMIC DRUGS MONITORING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 27: GLOBAL IMMUNOSUPPRESSANTS MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 28: NORTH AMERICA: IMMUNOSUPPRESSANTS MONITORING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 29: GLOBAL ANTIBIOTICS MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 30: NORTH AMERICA: ANTIBIOTICS MONITORING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 31: GLOBAL BRONCHODILATORS MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 32: NORTH AMERICA: BRONCHODILATORS MONITORING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 33: GLOBAL PSYCHOACTIVE DRUGS MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 34: NORTH AMERICA: PSYCHOACTIVE DRUGS MONITORING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 35: OTHER THERAPEUTIC DRUG CLASSES MONITORING MARKET SIZE , BY REGION, 2013-2020 (USD MILLION)
  • TABLE 36: TDM MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 37: TDM MARKET SIZE FOR HOSPITAL LABS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 38: TDM MARKET SIZE FOR COMMERCIAL/PRIVATE LABS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 39: TDM MARKET SIZE FOR OTHER END USERS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 40: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 41: NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 42: NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 43: NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 44: NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SIZE FOR IMMUNOASSAYS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 45: NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SIZE FOR PROTEOMICS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 46: NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLASS OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 47: NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 48: U.S.: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 49: U.S.: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 50: U.S.: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 51: U.S.: THERAPEUTIC DRUG MONITORING MARKET SIZE FOR IMMUNOASSAYS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 52: U.S.: THERAPEUTIC DRUG MONITORING MARKET SIZE FOR PROTEOMICS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 53: U.S.: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLASS OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 54: U.S.: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 55: CANADA: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 56: CANADA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 57: CANADA: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 58: CANADA: THERAPEUTIC DRUG MONITORING MARKET SIZE FOR IMMUNOASSAYS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 59: CANADA: THERAPEUTIC DRUG MONITORING MARKET SIZE FOR PROTEOMICS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 60: CANADA: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLASS OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 61: CANADA: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 62: EUROPE: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 63: EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 64: EUROPE: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 65: EUROPE: THERAPEUTIC DRUG MONITORING MARKET SIZE FOR IMMUNOASSAYS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 66: EUROPE: THERAPEUTIC DRUG MONITORING MARKET SIZE FOR PROTEOMICS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 67: EUROPE: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLASS OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 68: EUROPE: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 69: APAC: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 70: APAC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 71: APAC: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 72: APAC: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 73: ROW: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 74: ROW: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 75: ROW: THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 76: NEW PRODUCT LAUNCHES, PRODUCT APPROVALS, AND PATENTS, 2012-2015
  • TABLE 77: ACQUISITIONS, 2012-2015
  • TABLE 78: MARKETING AND PROMOTIONS , 2012-2015
  • TABLE 79: AGREEMENTS, 2012-2015
  • TABLE 80: OTHER DEVELOPMENTS, 2012-2015

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN: THERAPEUTIC DRUG MONITORING MARKET
  • FIGURE 2: MARKET SIZE ESTIMATION
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: DATA TRIANGULATION METHODOLOGY
  • FIGURE 5: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT (2015 VS. 2020)
  • FIGURE 6: CONSUMABLES ACCOUNT FOR A MAJOR SHARE OF THE THERAPEUTIC DRUG MONITORING MARKET IN 2015
  • FIGURE 7: CHEMILUMINISCENT ASSAYS (CLIA) TO DOMINATE THE THERAPEUTIC DRUG MONITORING MARKET DURING THE FORECAST PERIOD
  • FIGURE 8: ANTIEPILEPTICS TO WITNESS THE HIGHEST GROWTH RATE IN THE THERAPEUTIC DRUG MONITORING MARKET FOR CLASS OF DRUG FROM 2015 TO 2020
  • FIGURE 9: HOSPITAL LABORATORIES TO DOMINATE THE THERAPEUTIC DRUG MONITORING MARKET IN THE FORECAST PERIOD
  • FIGURE 10: GEOGRAPHICAL SNAPSHOT OF THE THERAPEUTIC DRUG MONITORING MARKET, 2015
  • FIGURE 11: RISING FOCUS ON PHARMACOGENETIC TESTING IS DRIVING GROWTH IN THE THERAPEUTIC DRUG MONITORING MARKET
  • FIGURE 12: ANTIEPILEPTICS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE IN 2015
  • FIGURE 13: NORTH AMERICA WILL BE THE FASTEST-GROWING MARKET FROM 2015 TO 2020
  • FIGURE 14: IMMUNOASSAYS SEGMENT TO WITNESS THE HIGHEST GROWTH RATE FROM 2015 TO 2020
  • FIGURE 15: IMMUNOASSAY ANALYZERS TO DOMINATE THE THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET IN 2015
  • FIGURE 16: THERAPEUTIC DRUG MONITORING: MARKET SEGMENTATION
  • FIGURE 17: GLOBAL THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 18: THE CONSUMABLES SEGMENT WILL DOMINATE THE THERAPEUTIC DRUG MONITORING PRODUCTS MARKET DURING THE FORECAST PERIOD (2015-2020)
  • FIGURE 19: NORTH AMERICA TO CONTRIBUTE TO MORE THAN HALF OF THE THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET IN THE FORECAST PERIOD
  • FIGURE 20: IMMUNOASSAY ANALYZERS TO WITNESS HIGHEST GROWTH IN THE THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET FROM 2015 TO 2020
  • FIGURE 21: THERAPEUTIC DRUG MONITORING MARKET SEGMENTATION, BY TECHNOLOGY
  • FIGURE 22: IMMUNOASSAYS SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 23: CLIA IS EXPECTED TO DOMINATE THE GLOBAL IMMUNOASSAYS IN THERAPEUTIC DRUG MONITORING MARKET IN 2015
  • FIGURE 24: NORTH AMERICA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CLIA IN THERAPEUTIC DRUG MONITORING MARKET DURING THE FORECAST PERIOD
  • FIGURE 25: LC-MS TO DOMINATE THE PROTEOMIC TECHNOLOGIES IN THERAPEUTIC DRUG MONITORING MARKET FROM 2015 TO 2020
  • FIGURE 26: NORTH AMERICA IS EXPECTED TO GROW AT A HIGHER CAGR IN THE LC-MS IN THERAPEUTIC DRUG MONITORING MARKET DURING THE FORECAST PERIOD
  • FIGURE 27: ANTIEPILEPTICS TO DOMINATE THE THERAPEUTIC DRUG MONITORING MARKET DURING THE FORECAST PERIOD
  • FIGURE 28: NORTH AMERICA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ANTIEPILEPTICS MONITORING MARKET IN 2015
  • FIGURE 29: U.S. TO WITNESS THE HIGHEST GROWTH IN THE ANTIARRHYTHMIC DRUGS MONITORING MARKET IN NORTH AMERICA
  • FIGURE 30: NORTH AMERICA IS EXPECTED TO WITNESS THE HIGHEST GROWTH IN THE IMMUNOSUPPRESSANTS MONITORING MARKET DURING THE FORECAST PERIOD
  • FIGURE 31: NORTH AMERICA TO ACCOUNT FOR MORE THAN HALF THE GLOBAL ANTIBIOTICS MONITORING MARKET IN 2015
  • FIGURE 32: HOSPITAL LABS TO DOMINATE THE MARKET, BY END USER
  • FIGURE 33: NORTH AMERICA HOLDS LARGEST SHARE OF THE HOSPITAL LABS END-USER SEGMENT
  • FIGURE 34: NORTH AMERICA EXPECTED TO GROW AT THE FASTEST RATE IN THE COMMERCIAL/PRIVATE LABS SEGMENT
  • FIGURE 35: NORTH AMERICA TO LEAD THE THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS
  • FIGURE 36: GEOGRAPHIC SNAPSHOT (2015): NORTH AMERICA WILL BE THE FASTEST-GROWING REGION BY 2020
  • FIGURE 37: NORTH AMERICA, AN ATTRACTIVE DESTINATION FOR THE THERAPEUTIC DRUG MONITORING MARKET
  • FIGURE 38: NORTH AMERICA THERAPEUTIC DRUG MARKET SNAPSHOT
  • FIGURE 39: IMMUNOASSAY ANALYZERS ESTIMATED TO DOMINATE THE NORTH AMERICA THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET IN 2015
  • FIGURE 40: CLIA ESTIMATED TO BE THE FASTEST-GROWING SEGMENT IN THE U.S. THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS
  • FIGURE 41: EUROPE THERAPEUTIC DRUG MARKET SNAPSHOT
  • FIGURE 42: ANTIEPILEPTIC DRUGS TO DOMINATE EUROPEAN MARKET IN 2015
  • FIGURE 43: HOSPITAL LABORATORIES TO ACCOUNT FOR THE LARGEST SHARE OF THE THERAPEUTIC DRUG MONITORING MARKET, BY END USER, IN APAC
  • FIGURE 44: COMPANIES ADOPTED NEW PRODUCT LAUNCHES AS THEIR KEY GROWTH STRATEGY OVER THE LAST THREE YEARS (2013-2016)
  • FIGURE 45: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES, PRODUCT APPROVALS, AND PATENTS-KEY GROWTH STRATEGY ADOPTED BY PLAYERS IN THE THERAPEUTIC DRUG MONITORING MARKET
  • FIGURE 46: GEOGRAPHIC REVENUE MIX OF THE TOP THREE MARKET PLAYERS
  • FIGURE 47: COMPANY SNAPSHOT: ROCHE DIAGNOSTICS
  • FIGURE 48: COMPANY SNAPSHOT: SIEMENS HEALTHCARE
  • FIGURE 49: COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC.
  • FIGURE 50: COMPANY SNAPSHOT: DANAHER CORPORATION
  • FIGURE 51: COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC.
  • FIGURE 52: COMPANY SNAPSHOT: ABBOTT LABORATORIES
  • FIGURE 53: COMPANY SNAPSHOT: AGILENT TECHNOLOGIES
  • FIGURE 54: COMPANY SNAPSHOT: BIOMERIEUX
  • FIGURE 55: COMPANY SNAPSHOT: ALERE INC.
Back to Top